{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T17:34:23Z","timestamp":1760549663993,"version":"3.40.5"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,12,12]],"date-time":"2014-12-12T00:00:00Z","timestamp":1418342400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1007\/s00417-014-2856-3","type":"journal-article","created":{"date-parts":[[2014,12,11]],"date-time":"2014-12-11T05:58:59Z","timestamp":1418277539000},"page":"457-465","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Anti-interferon alpha antibodies and autoantibodies in patients with Beh\u00e7et\u2019s disease uveitis treated with recombinant human interferon alpha-2a"],"prefix":"10.1007","volume":"253","author":[{"given":"\u00d6zlem","family":"Aydinoglu-Candan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bilge","family":"Araz-Er\u015fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmet","family":"Gul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selim","family":"Badur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilknur","family":"Tugal-Tutkun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,12,12]]},"reference":[{"issue":"1","key":"2856_CR1","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2174\/1568010053622894","volume":"4","author":"A G\u00fcl","year":"2005","unstructured":"G\u00fcl A (2005) Beh\u00e7et\u2019s disease as an autoinflammatory disorder. Curr Drug Targets Inflamm Allergy 4(1):81\u201383","journal-title":"Curr Drug Targets Inflamm Allergy"},{"issue":"11","key":"2856_CR2","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s10067-010-1491-6","volume":"29","author":"VD Kapsimali","year":"2010","unstructured":"Kapsimali VD, Kanakis MA, Vaiopoulos GA, Kaklamanis PG (2010) Etiopathogenesis of Beh\u00e7et\u2019s disease with emphasis on the role of immunological aberrations. Clin Rheumatol 29(11):1211\u20131216","journal-title":"Clin Rheumatol"},{"issue":"12","key":"2856_CR3","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1093\/rheumatology\/kel329","volume":"45","author":"H Direskeneli","year":"2006","unstructured":"Direskeneli H (2006) Autoimmunity vs autoinflammation in Behcet\u2019s disease: do we oversimplify a complex disorder? Rheumatology (Oxford) 45(12):1461\u20131465","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"2856_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/08830189709116840","volume":"14","author":"H Yaz\u0131c\u0131","year":"1997","unstructured":"Yaz\u0131c\u0131 H (1997) The place of Behcet\u2019s Syndrome among the autoimmune diseases. Intern Rev Immunol 14(1):1\u201310","journal-title":"Intern Rev Immunol"},{"issue":"Suppl 1","key":"2856_CR5","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1186\/ar2886","volume":"12","author":"MK Crow","year":"2010","unstructured":"Crow MK (2010) Type I interferon in organ-targeted autoimmune and inflammatory diseases. Arthritis Res Ther 12(Suppl 1):S5","journal-title":"Arthritis Res Ther"},{"issue":"27","key":"2856_CR6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.immuni.2012.01.007","volume":"36","author":"V Pascual","year":"2012","unstructured":"Pascual V, Banchereau J (2012) Tracking interferon in autoimmunity. Immunity 36(27):7\u20139","journal-title":"Immunity"},{"issue":"10","key":"2856_CR7","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1084\/jem.20101664","volume":"207","author":"G Trinchieri","year":"2010","unstructured":"Trinchieri G (2010) Type I interferon: friend or foe? J Exp Med 207(10):2053\u20132063","journal-title":"J Exp Med"},{"issue":"4","key":"2856_CR8","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1073\/pnas.91.4.1198","volume":"91","author":"JU Gutterman","year":"1994","unstructured":"Gutterman JU (1994) Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci U S A 91(4):1198\u20131205","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"2856_CR9","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1002\/art.27581","volume":"62","author":"CM Deuter","year":"2010","unstructured":"Deuter CM, Zierhut M, M\u00f6hle A, Vonthein R, St\u00f6biger N, K\u00f6tter I (2010) Long-term remission after cessation of interferon-alpha treatment in patients with severe uveitis due to Beh\u00e7et\u2019s disease. Arthritis Rheum 62(9):2796\u20132805","journal-title":"Arthritis Rheum"},{"issue":"12","key":"2856_CR10","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1007\/s00417-006-0346-y","volume":"244","author":"I Tugal-Tutkun","year":"2006","unstructured":"Tugal-Tutkun I, G\u00fcney-Tefekli E, Urgancioglu M (2006) Results of interferon-alfa therapy in patients with Beh\u00e7et uveitis. Graefes Arch Clin Exp Ophthalmol 244(12):1692\u20131695","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"2856_CR11","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/bjo.87.4.423","volume":"87","author":"I K\u00f6tter","year":"2003","unstructured":"K\u00f6tter I, Zierhut M, Eckstein AK et al (2003) Human recombinant interferon alfa-2a for the treatment of Beh\u00e7et\u2019s disease with sight threatening posterior or panuveitis. Br J Ophthalmol 87(4):423\u2013431","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"2856_CR12","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.semarthrit.2003.09.005","volume":"33","author":"I K\u00f6tter","year":"2004","unstructured":"K\u00f6tter I, Vonthein R, Zierhut M et al (2004) Differential efficacy of human recombinant interferon- 2a on ocular and extraocular manifestations of behcet disease: results of an open 4-center trial. Semin Arthritis Rheum 33(5):311\u2013319","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"2856_CR13","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.semarthrit.2003.09.010","volume":"33","author":"I K\u00f6tter","year":"2004","unstructured":"K\u00f6tter I, G\u00fcnaydin I, Zierhut M, St\u00fcbiger N (2004) The use of interferon alpha in Beh\u00e7et disease: review of the literature. Semin Arthritis Rheum 33(5):320\u2013335","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"2856_CR14","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1076\/ocii.8.4.293.6453","volume":"8","author":"B Wechsler","year":"2000","unstructured":"Wechsler B, Bodaghi B (2000) Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Beh\u00e7et\u2019s disease. Ocul Immunol Inflamm 8(4):293\u2013301","journal-title":"Ocul Immunol Inflamm"},{"issue":"11","key":"2856_CR15","first-page":"928","volume":"4","author":"V Hamuryudan","year":"2002","unstructured":"Hamuryudan V, Ozyazgan Y, Fresko I (2002) Interferon alfa combined with azathioprine for the uveitis of Beh\u00e7et\u2019s disease: an open study. Isr Med Assoc J 4(11):928\u2013930","journal-title":"Isr Med Assoc J"},{"issue":"6","key":"2856_CR16","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.ajo.2008.08.038","volume":"146","author":"J Gueudry","year":"2008","unstructured":"Gueudry J, Wechsler B, Terrada C et al (2008) Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Beh\u00e7et disease. Am J Ophthalmol 146(6):837\u2013844","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"2856_CR17","first-page":"896","volume":"35","author":"L Krause","year":"2008","unstructured":"Krause L, Altenburg A, Pleyer U, K\u00f6hler AK, Zouboulis CC, Foerster MH (2008) Longterm visual prognosis of patients with ocular adamantiades-Beh\u00e7et\u2019s disease treated with interferon-alpha-2a. J Rheumatol 35(5):896\u2013903","journal-title":"J Rheumatol"},{"issue":"7","key":"2856_CR18","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.ophtha.2009.11.022","volume":"117","author":"G Sobaci","year":"2010","unstructured":"Sobaci G, Erdem U, Durukan AH et al (2010) Safety and effectiveness of interferon alpha-2a in treatment of patients with Beh\u00e7et\u2019s uveitis refractory to conventional treatments. Ophthalmology 117(7):1430\u20131435","journal-title":"Ophthalmology"},{"issue":"6","key":"2856_CR19","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.ajo.2009.03.009","volume":"147","author":"S Onal","year":"2009","unstructured":"Onal S, Kazokoglu H (2009) Low-dose interferon alfa-2a therapy in severe uveitis associated with Beh\u00e7et disease. Am J Ophthalmol 147(6):1109\u20131110","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"2856_CR20","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/archophthalmol.2011.3","volume":"129","author":"S Onal","year":"2011","unstructured":"Onal S, Kazokoglu H (2011) Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Beh\u00e7et uveitis. Arch Ophthalmol 129(3):288\u2013294","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"2856_CR21","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1089\/jop.2011.0238","volume":"28","author":"FN Yal\u00e7inda\u011f","year":"2012","unstructured":"Yal\u00e7inda\u011f FN, Uzun A (2012) Results of interferon alpha-2a therapy in patients with Behcet\u2019s disease. J Ocul Pharmacol Ther 28(4):439\u2013443","journal-title":"J Ocul Pharmacol Ther"},{"issue":"7","key":"2856_CR22","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1136\/bjo.2008.153874","volume":"93","author":"CM Deuter","year":"2009","unstructured":"Deuter CM, K\u00f6tter I, G\u00fcnaydin I, St\u00fcbiger N, Doycheva DG, Zierhut M (2009) Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis. Br J Ophthalmol 93(7):906\u2013913","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"2856_CR23","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/ICU.0b013e328010ab35","volume":"17","author":"F Mackensen","year":"2006","unstructured":"Mackensen F, Max R, Becker MD (2006) Interferon therapy for ocular disease. Curr Opin Ophthalmol 17(6):567\u2013573","journal-title":"Curr Opin Ophthalmol"},{"issue":"3","key":"2856_CR24","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/bjo.2006.101550","volume":"91","author":"B Bodaghi","year":"2007","unstructured":"Bodaghi B, Gendron G, Wechsler B et al (2007) Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol 91(3):335\u2013339","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"2856_CR25","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ajo.2007.03.050","volume":"144","author":"J Plskova","year":"2007","unstructured":"Plskova J, Greiner K, Forrester JV (2007) Interferon-alpha as an effective treatment for noninfectious posterior uveitis and panuveitis. Am J Ophthalmol 144(1):55\u201361","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"2856_CR26","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0168-8278(98)80309-7","volume":"28","author":"V Leroy","year":"1998","unstructured":"Leroy V, Baud M, Traversay C, Maynard-Muet M, Lebon P, Zarski JP (1998) Role of anti-interferon antibodies in breakthrough occurrence during alpha 2a and 2b therapy in patients with chronic hepatitis C. J Hepatol 28(3):375\u2013381","journal-title":"J Hepatol"},{"issue":"3","key":"2856_CR27","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1365-2249.1992.tb06957.x","volume":"89","author":"LE R\u00f6nnblom","year":"1992","unstructured":"R\u00f6nnblom LE, Janson ET, Perers A, Oberg KE, Alm GV (1992) Characterization of anti-interferon-a antibodies appearing during recombinant interferon-alfa 2a treatment. Clin Exp Immunol 89(3):330\u2013335","journal-title":"Clin Exp Immunol"},{"issue":"10","key":"2856_CR28","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/j.1365-2893.2012.01598.x","volume":"19","author":"F Matsuda","year":"2012","unstructured":"Matsuda F, Torii Y, Enomoto H et al (2012) Anti-interferon-\u03b1 neutralizing antibody is associated with nonresponse to pegylated interferon-\u03b1 plus ribavirin in chronic hepatitis C. J Viral Hepat 19(10):694\u2013703","journal-title":"J Viral Hepat"},{"issue":"7","key":"2856_CR29","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa053007","volume":"354","author":"H Gogas","year":"2006","unstructured":"Gogas H, Ioannovich J, Dafni U et al (2006) Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354(7):709\u2013718","journal-title":"N Engl J Med"},{"issue":"9","key":"2856_CR30","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.1167\/iovs.06-0058","volume":"47","author":"J Plskova","year":"2006","unstructured":"Plskova J, Greiner K, Muckersie E, Duncan L, Forrester JV (2006) Interferon-alpha: A key factor in autoimmune disease? Invest Ophthalmol Vis Sci 47(9):3946\u20133950","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"2856_CR31","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1046\/j.1365-2249.2003.02113.x","volume":"132","author":"A Meager","year":"2003","unstructured":"Meager A, Wadhwa M, Dilger P et al (2003) Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and\/or myasthenia gravis. Clin Exp Immunol 132(1):128\u2013136","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"2856_CR32","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/0090-1229(92)90250-R","volume":"65","author":"UB Wandl","year":"1992","unstructured":"Wandl UB, Nagel-Hiemke M, May D et al (1992) Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders. Clin Immunol Immunopathol 65(1):70\u20134","journal-title":"Clin Immunol Immunopathol"},{"issue":"3","key":"2856_CR33","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/BOR.0b013e3283368099","volume":"22","author":"I K\u00f6tter","year":"2010","unstructured":"K\u00f6tter I, Hamuryudan V, Ozturk ZE, Yazici H (2010) Interferon therapy in rheumatic diseases: state-of-the-art 2010. Curr Opin Rheumatol 22(3):278\u2013283","journal-title":"Curr Opin Rheumatol"},{"key":"2856_CR34","first-page":"350","volume-title":"Uveitis: fundamentals and clinical practice","author":"RB Nussenblatt","year":"2003","unstructured":"Nussenblatt RB (2003) Beh\u00e7et\u2019s disease. In: Nussenblatt RB, Whitcup SM (eds) Uveitis: fundamentals and clinical practice, 3rd edn. Mosby, Philadelphia, pp 350\u2013371","edition":"3"},{"issue":"8697","key":"2856_CR35","first-page":"1078","volume":"335","author":"International Study Group for Beh\u00e7et\u2019s Disease","year":"1990","unstructured":"International Study Group for Beh\u00e7et\u2019s Disease (1990) Criteria for diagnosis of Beh\u00e7et\u2019s disease. Lancet 335(8697):1078\u20131080","journal-title":"Lancet"},{"key":"2856_CR36","doi-asserted-by":"crossref","unstructured":"Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature (SUN) Working Group (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 140(3):509\u2013516","DOI":"10.1016\/j.ajo.2005.03.057"},{"issue":"5","key":"2856_CR37","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.ajo.2004.12.009","volume":"139","author":"DA Jabs","year":"2005","unstructured":"Jabs DA (2005) Improving the reporting of clinical case series. Am J Ophthalmol 139(5):900\u2013905","journal-title":"Am J Ophthalmol"},{"issue":"1\u20132","key":"2856_CR38","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jneuroim.2007.10.015","volume":"194","author":"RA Pachner","year":"2008","unstructured":"Pachner RA (2008) Measurement of binding anti-IFNbeta antibodies in IFNbeta-treated MS patients: lessons for the clinician and basic scientist. J Neuroimmunol 194(1\u20132):5\u20136","journal-title":"J Neuroimmunol"},{"issue":"11","key":"2856_CR39","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/j.1468-1331.2005.01386.x","volume":"12","author":"PS S\u00f8rensen","year":"2005","unstructured":"S\u00f8rensen PS, Deisenhammer F, Duda P et al (2005) Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS task force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 12(11):817\u2013827","journal-title":"Eur J Neurol"},{"issue":"10","key":"2856_CR40","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1111\/j.1468-1331.2012.03721.x","volume":"19","author":"PE Jensen","year":"2012","unstructured":"Jensen PE, Sellebjerg F, S\u00f8ndergaard HB, S\u00f8rensen PS (2012) Correlation between anti-interferon-\u03b2 binding and neutralizing antibodies in interferon-\u03b2-treated multiple sclerosis patients. Eur J Neurol 19(10):1311\u20131317","journal-title":"Eur J Neurol"},{"issue":"2","key":"2856_CR41","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.cellimm.2011.08.002","volume":"271","author":"EH Ibrahim","year":"2011","unstructured":"Ibrahim EH (2011) Anti-IFN autoantibodies are present in healthy Egyptian blood donors at low titer. Cell Immunol 271(2):365\u2013370","journal-title":"Cell Immunol"},{"issue":"9391","key":"2856_CR42","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/S0140-6736(03)14541-2","volume":"362","author":"PS Sorensen","year":"2003","unstructured":"Sorensen PS, Ross C, Clemmesen KM et al (2003) Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 362(9391):1184\u20131191","journal-title":"Lancet"},{"issue":"1\u20132","key":"2856_CR43","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jneuroim.2009.03.009","volume":"210","author":"M Lap\u00e9 Nixon","year":"2009","unstructured":"Lap\u00e9 Nixon M, Matud J, Yeh C, Prince HE (2009) Evaluation of a multiplex bead-based screening assay for detection of binding antibodies to interferon-beta. J Neuroimmunol 210(1\u20132):104\u2013107","journal-title":"J Neuroimmunol"},{"issue":"10","key":"2856_CR44","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1136\/bjo.2004.061119","volume":"89","author":"MD Becker","year":"2005","unstructured":"Becker MD, Heiligenhaus A, Hudde T et al (2005) Interferon as a treatment for uveitis associated with multiple sclerosis. Br J Ophthalmol 89(10):1254\u20137","journal-title":"Br J Ophthalmol"},{"issue":"1\u20132","key":"2856_CR45","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jneuroim.2007.08.007","volume":"190","author":"HE Prince","year":"2007","unstructured":"Prince HE, Lap\u00e9-Nixon M, Audette C, Van Horn K (2007) Identification of interferon-beta antibodies in a reference laboratory setting: findings for 1144 consecutive sera. J Neuroimmunol 190(1\u20132):165\u2013169","journal-title":"J Neuroimmunol"},{"issue":"12","key":"2856_CR46","first-page":"581","volume":"57","author":"H Qureshi","year":"2007","unstructured":"Qureshi H, Arif A, Ahmed W et al (2007) Role of interferon anti body in predicting the response to interferon therapy in HCV patients. J Pak Med Assoc 57(12):581\u2013583","journal-title":"J Pak Med Assoc"},{"issue":"4-1","key":"2856_CR47","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1600-0676.1992.tb01041.x","volume":"12","author":"R Wejst\u00e5l","year":"1992","unstructured":"Wejst\u00e5l R, Norkrans G, Lenkei R, Weiland O, Schvarcz R, Fryd\u00e9n A (1992) Peripheral blood lymphocyte subsets in patients with chronic hepatitis C\u2013effects of interferon treatment. Liver 12(4-1):161\u2013167","journal-title":"Liver"},{"issue":"10","key":"2856_CR48","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1093\/rheumatology\/keh311","volume":"43","author":"M Treusch","year":"2004","unstructured":"Treusch M, Vonthein R, Baur M et al (2004) Influence of human recombinant interferon-alpha2a (rhIFN-alpha2a) on altered lymphocyte subpopulations and monocytes in Behcet\u2019s disease. Rheumatology 43(10):1275\u20131282","journal-title":"Rheumatology"},{"issue":"4","key":"2856_CR49","doi-asserted-by":"crossref","first-page":"248","DOI":"10.2169\/internalmedicine.36.248","volume":"36","author":"M Wada","year":"1997","unstructured":"Wada M, Kang KB, Kinugasa A et al (1997) Does the presence of serum autoantibodies influence the responsiveness to interferon-alpha 2a treatment in chronic hepatitis C? Intern Med 36(4):248\u2013254","journal-title":"Intern Med"},{"issue":"2","key":"2856_CR50","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1200\/JCO.1999.17.2.529","volume":"17","author":"A Franzke","year":"1999","unstructured":"Franzke A, Peest D, Probst-Kepper M et al (1999) Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer. J Clin Oncol 17(2):529\u2013533","journal-title":"J Clin Oncol"},{"key":"2856_CR51","doi-asserted-by":"crossref","unstructured":"Galeone M, Colucci R, D\u2019Erme AM, Moretti S, Lotti T. Potential infectious etiology of Beh\u00e7et\u2019s disease. Patholog Res Int 2012;2012:595380","DOI":"10.1155\/2012\/595380"},{"key":"2856_CR52","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(13)60954-X","volume":"382","author":"M Wahren-Herlenius","year":"2013","unstructured":"Wahren-Herlenius M, D\u00f6rner T (2013) Immunopathogenic mechanisms of systemic autoimmune disease. Lancet 382:819\u201331","journal-title":"Lancet"},{"issue":"1","key":"2856_CR53","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/BOR.0000000000000003","volume":"26","author":"A G\u00fcl","year":"2014","unstructured":"G\u00fcl A (2014) Genetics of Beh\u00e7et\u2019s disease: lessons learned from genomewide association studies. Curr Opin Rheumatol 26(1):56\u201363","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"2856_CR54","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ajo.2006.04.016","volume":"142","author":"JK Ahn","year":"2006","unstructured":"Ahn JK, Yu G, Chung H, Park YG (2006) Intraocular cytokine environment in active Beh\u00e7et uveitis. Am J Ophthalmol 142(3):429\u2013434","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"2856_CR55","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.clim.2011.01.014","volume":"139","author":"AM El-Asrar","year":"2011","unstructured":"El-Asrar AM, Struyf S, Kangave D et al (2011) Cytokine profiles in aqueous humor of patients with different clinical entities of endogenous uveitis. Clin Immunol 139(2):177\u2013184","journal-title":"Clin Immunol"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-014-2856-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-014-2856-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-014-2856-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:33:45Z","timestamp":1747182825000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-014-2856-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,12]]},"references-count":55,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["2856"],"URL":"https:\/\/doi.org\/10.1007\/s00417-014-2856-3","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"type":"print","value":"0721-832X"},{"type":"electronic","value":"1435-702X"}],"subject":[],"published":{"date-parts":[[2014,12,12]]}}}